Wuhan Huagong Life Technology Joint-stock Co., Ltd.

Wuhan Huazhong University of Science and Technology Life Technology Co., Ltd. was established in July 2005, mainly engaged in the manufacturing and sales of pharmaceutical active pharmaceutical ingredients and pharmaceutical intermediates; research and development, technology transfer, technical services of chemical and pharmaceutical products, and related import and export business. The company owns a wholly-owned subsidiary — Wuhan Xinxue Pharmaceutical Co., Ltd., and a controlling subsidiary — Tianjin Haoyang Biological Products Technology Co., Ltd.
The company is located in the Science and Technology Park of Huazhong University of Science and Technology in Wuhan East Lake New Technology Development Zone, relying on the technology development of Huazhong University of Science and Technology, the enterprise development strives for a high starting point, and is committed to becoming a polysaccharide polymer drug manufacturing enterprise with technical characteristics and advantages nationwide.
The company's main product — medium molecular weight hydroxyethyl starch API, its preparation is a mainstream product of world plasma substitutes, and is a * drug for the treatment and prevention of hypovolemia and shock. In the course of development, the company broke through the production technology of HES200/0.5; realized the industrialization of HES200/0.5; product quality is *, reaching the international advanced level; domestically realized the foreign trade export of HES200/0.5 and HES130/0.4 products.
The company's "Study on the Synthesis Process of Hydroxyethyl Starch" won the first prize of Hubei Provincial Science and Technology Progress Award, and it owns two invention patents. The company has completed the registration of medium molecular plasma substitute API in 4 overseas countries, and its products have been exported to more than a dozen countries. It is currently a domestic manufacturer specializing in the production of medium molecular hydroxyethyl starch API.
The company adheres to the development direction of polymer drugs, and in the spirit of focusing on products, has realized the serialization of medium molecular weight plasma substitute products, and can provide plasma substitute products with different molecular weights and different quality standard requirements for preparation manufacturers producing Penta starch, Heta starch, and Tetra starch, and is expanding into polymer iron supplement drugs and polysaccharide drugs, reserving a number of polymer-related drug projects with early development, high technical level, and broad market prospects, injecting vitality and momentum into the development of the enterprise.
The company is located on the beautiful Tangxun Lake, and the beautiful factory environment adds to the enterprise's responsibility to protect the environment. Preventing from the source, continuously improving the process technology level, reducing emissions, and treating pollution in compliance, the company insists on taking the path of sustainable development in harmony with the environment.
The company follows the corporate culture concept of "efficient, rigorous, truth-seeking, and cooperative". We rely on highly specialized technical and management talents, excellent manufacturing processes, and excellent product quality, based domestically and facing internationally, to achieve the healthy development of the enterprise.
We are proud of the products we produce, and proud to bring health to those in need!